Study finds adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence
A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer ...
Mar 21, 2024
0
182